Biopathologic Features of Hodgkin's Disease

References

• Anastasi J., Bauer K.D., Variakojis D. DNA aneu-ploidy in Hodgkin's disease. A multiparameter flow-cytometric analysis with cytologic correlation. Am. J. Pathol. 1987; 128: 573
   PubMed Web of Science ®Google Scholar
• Haber M.M., Liu J., Knowles D.M., Inghirami G. Determination of the DNA content of the Reed-Sternberg cell of Hodgkin's disease by image analysis. Blood 1992; 80: 2851
   PubMed Web of Science ®Google Scholar
• Gerdes J., Van Baarlen J., Piled S., Schwarting R., Van Unnik J.A.M., Stein H. Tumor cell growth fraction in Hodgkin's disease. Am. J. Pathol. 1987; 128: 390
   PubMed Web of Science ®Google Scholar
• Schmid C., Sweeney E., Isaacson P.G. Proliferating cell nuclear antigen (PCNA) expression in Hodgkin's disease. J. Pathol. 1992; 168: 1
   PubMed Web of Science ®Google Scholar
• Weiss L.M., Strickler J.G., Hu E., Warnke R.A., Sklar J. Immunoglobulin gene rearrangements in Hodgkin's disease. Hum. Pathol. 1986; 17: 1009
   PubMed Web of Science ®Google Scholar
• Brinker M.G.L., Poppema S., Buys C. H. C. M., Timens W., Osinga J., Visser L. Clonal immunoglobulin gene rearrangements in tissues involved by Hodgkin's disease. Blood 1987; 70: 186
   PubMed Web of Science ®Google Scholar
• Sundeen J., Lipford E., Uppenkamp M., Sussman E., Wahl L., Raffeld M., Cossman J. Rearranged antigen receptor genes in Hodgkin's disease. Blood 1987; 70: 96
   PubMed Web of Science ®Google Scholar
• Knowles D.M., Neri A., Pelicci P.G., Burke J.S., Wu A., Winberg C.D., Sheibani K., Dalla-Favera R. Immunoglobulin and T-cell receptor beta-chain gene rearrangement analysis of Hodgkin's disease: implications for lineage determination and differential diagnosis. Proc. Natl. Acad. Sci. USA 1986; 83: 7942
   PubMed Web of Science ®Google Scholar
• Roth M.S., Schnitzer B., Bingham E.L., Hamden C.E., Hyder D.M., Ginsburg D. Rearrangement of immunoglobulin and T-cell receptor genes in Hodgkin's disease. Am. J. Pathol. 1988; 131: 331
   PubMed Web of Science ®Google Scholar
• Hu E.H.L., Ellison D., Zovich D., Nichols P., Pattengale P. Molecular analysis of Hodgkin's disease with abundant Reed-Stemberg cells. Hemat. Pathol. 1990; 4: 27
   PubMedGoogle Scholar
• Weiss L.M., Chang K.L. Molecular biologic studies of Hodgkin's disease. Sem. Diagn. Pathol. 1992; 9: 272
   PubMed Web of Science ®Google Scholar
• Levine J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature 1991; 351: 453
   PubMed Web of Science ®Google Scholar
• Yonosh-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 1991; 352: 345
   PubMed Web of Science ®Google Scholar
• Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304
   PubMed Web of Science ®Google Scholar
• Lane D.P. p53, guardian of the genome. Nature 1992; 358: 15
   PubMed Web of Science ®Google Scholar
• Kuerbitz S., Plunkett B., Walsh W., Kastan M. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 1992; 89: 7491
   PubMed Web of Science ®Google Scholar
• Nigro J.M., Baker S.J., Preisinger A.C., Jessup J.M., Hostetter R., Cleary K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C., Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 342: 705
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991; 253: 49
   PubMed Web of Science ®Google Scholar
• Lane D.P., Benchimol S. P53: oncogene or anti-onco-gene?. Genes Dev 1990; 4: 1
   PubMed Web of Science ®Google Scholar
• Gupta R.K., Patel K., Bodmer W.F., Bodmer J.G. Mutation of p53 in primary biopsy material and cell lines from Hodgkin's disease. Proc. Natl. Acad. Sci. USA 1993; 90: 2817
   PubMed Web of Science ®Google Scholar
• Trumper L.H., Brady G., Bagg A., Gray D., Loke S.L., Griesser H., Wagman R., Braziel R., Gascoyne R.D., Vicini S., Iscove N.N., Cossman J., Mak T. Single-cell analysis of Hodgkin and Reed-Sternberg cells: molecular heterogeneity of gene expression and p53 mutations. Blood 1993; 81: 3097
   PubMed Web of Science ®Google Scholar
• Doglioni C., Pelosio P., Mombello A., Scarpa A., Chilosi M. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol. Pathol. 1991; 5: 67
   PubMedGoogle Scholar
• Gupta R.K., Norton A.J., Thompson I.W., Lister T.A., Bodmer J.G. p53 expression in Reed-Stemberg cells of Hodgkin's disease. Br. J. Cancer 1992; 66: 649
   PubMed Web of Science ®Google Scholar
• Said J.W., Barrera R., Shintaku I.P., Nakamura H., Koeffler H.P. Immunohistochemical analysis of p53 expression in malignant lymphomas. Am. J. Pathol. 1992; 141: 1343
   PubMed Web of Science ®Google Scholar
• Momand J., Zambetti G.P., Olson D.C., George D., Levine A.J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 691: 1237
   Web of Science ®Google Scholar
• Luka J., Jomvall H., Klein G. Purification and biochemical characterization of the Epstein-Barr virus-determined nuclear antigen and an associated protein with a 53,000 dalton subunit. J. Virol. 1980; 35: 592
   PubMed Web of Science ®Google Scholar
• Barak Y., Juven T., Haffner R., Oren M. Mdm2 expression is induced by wild type p53 activity. EMBO J. 1993; 12: 461
   PubMed Web of Science ®Google Scholar
• Oliner J.D., Pietenpol J.A., Thiagalingam S., Gyuris J., Kinzler K.W., Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857
   PubMed Web of Science ®Google Scholar
• Leach F.S., Tokino T., Meltzer P., Burrell M., Oliner J.D., Smith S., Hill D.E., Sidransky D., Kinzler K.W., Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53: 2231
   PubMed Web of Science ®Google Scholar
• Niedobitek G., Rowlands D.C., Young L.S., Herbst H., Williams A., Hall P., Padfield J., Rooney N., Jones E.L. Overexpression of p53 in Hodgkin's disease: Lack of correlation with Epstein-Barr virus infection. J. Pathol. 1993; 169: 207
   PubMed Web of Science ®Google Scholar
• Hockenbery D.M., Zutter M., Hickey W., Nahm M., Korsmeyer S.J. Bc12 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. USA 1991; 88: 6961
   PubMed Web of Science ®Google Scholar
• Cleary M.L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. USA 1985; 82: 7439
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson M., Crush-Stanton S., Cossman J. Involvementofthebcl-2 gene in Hodgkin's disease. Natl. Cancer Inst. 1990; 82: 855
   Google Scholar
• Gupta R.K., Whelan J.S., Lister A., Young B.D., Bodmer J.G. Direct sequence analysis of the t(14;18) chromosomal translocation in Hodgkin's disease. Blood 1992; 79: 2084
   PubMed Web of Science ®Google Scholar
• Reid A.H., Cunningham R.E., Frizzera G., O'Leary T.J. Bcl-2 rearrangement in Hodgkin's disease. Results of polymerase chain reaction, flow cytometry, and sequencing on formalin-fixed, paraffin-embedded tissue. Am. J. Pathol. 1993; 142: 395
   PubMed Web of Science ®Google Scholar
• Louie D.C., Kant J.A., Brooks J.J., Reed J.C. Absence of t(14;18) major and minor breakpoints and of bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 1991; 139: 1231
   PubMed Web of Science ®Google Scholar
• Schmid C., Pan L., Diss T., Isaacson P.G. Expression of B-cell antigens by Hodgkin's and Reed-Stemberg cells. Am. J. Pathol. 1991; 139: 701
   PubMed Web of Science ®Google Scholar
• Athan E., Chadburn A., Knowles D.M. The bcl-2 gene translocation is undetectable in Hodgkin's disease by Southern blot hybridization and polymerase chain reaction. Am. J. Pathol. 1992; 141: 193
   PubMed Web of Science ®Google Scholar
• LeBrun D.P., Ngan B.Y., Weiss L.M., Huie P., Wamke R.A., Geary M.L. The bcl-2 oncogene in Hodgkin's disease arising in the setting of follicular non-Hodgkin's lymphoma. Blood 1994; 83: 223
   PubMed Web of Science ®Google Scholar
• Herbst H., Niedobitek G. Epstein-Barr virus and Hodgkin's disease. Int. J. Clin. Lab. Res. 1993; 23: 13
   PubMedGoogle Scholar
• Weiss L.M., Movahed L.A., Wamke R.A., Sklar J. Detection of Epstein-Barr genomes in Reed-Sternberg cells of Hodgkin's disease. N. Engl. J. Med 1989; 320: 502
   PubMed Web of Science ®Google Scholar
• Herbst H., Niedobitek G., Kneba M., Hummel M., Finn T., Anagnostopoulos I., Bergholz M., Krieger G., Stein H. High incidence of Epstein-Barr virus genomes in Hodgkin' s disease. Am. J. Pathol. 1990; 137: 13
   PubMed Web of Science ®Google Scholar
• Weiss L.M., Chen Y.Y., Liu X.F., Shibata D. Epstein-Barr virus and Hodgkin's disease. Am. J. Pathol. 1991; 139: 1259
   PubMed Web of Science ®Google Scholar
• Pallesen G., Hamilton-Dutoit S.J., Rowe M., Young L.S. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet 1991; 337: 320
   PubMed Web of Science ®Google Scholar
• Herbst H., Steinbrecher E., Niedobitek G., Young L.S., Brooks L., Muller-Lantzsch N., Stein H. Distribution and phe-notype of Epstein-Barr virus-harboring cells in Hodgkin's disease. Blood 1992; 80: 484
   PubMed Web of Science ®Google Scholar
• Anagnostopoulos I., Herbst H., Niedobitek G., Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Kl-1 -positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74: 810
   PubMed Web of Science ®Google Scholar
• Chang K.L., Albujar P.F., Chen Y.Y., Johnson R.M., Weiss L.M. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood 1993; 81: 496
   PubMed Web of Science ®Google Scholar
• Uccini S., Monardo F., Ruco L.P., Baroni C.D., Faggioni A., Agliano A.M., Gradilone A., Manzari V., Vago L., Costanzi G., Carbone A., Boiocchi M., De Re V. High frequency of Epstein-Barr virus genome in HIV positive patients with Hodgkin's disease. Lancet 1989; 1: 1458
   PubMed Web of Science ®Google Scholar
• O'Grady J., Stewart S., Elton R.A., Krajeski A.S. Epstein-Barr virus in Hodgkin's disease and site of origin of tumor. Lancet 1994; 343: 265
   PubMed Web of Science ®Google Scholar
• Jarret R.F., Gallagher A., Jones D.B., Alexander F.E., Krajewski A.S., Kelsey A., Adams J., Angus B., Gledhill S., Wright D.H., Cartwright R.A., Onions D.E. Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age. J. Clin. Pathol. 1991; 44: 844
   PubMed Web of Science ®Google Scholar
• Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 1107
   PubMed Web of Science ®Google Scholar
• Knecht H., Bachmann E., Brousset P., Sandvej K., Nadal D., Bachman F., Odermatt B.F., Delsol G., Pallesen G. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993; 82: 2937
   PubMed Web of Science ®Google Scholar
• Khan G., Gupta R.K., Coates P.J., Slavin G. Epstein-Barr virus infection and bcl-2 proto-oncogene expression. Separate events in the pathogenesis of Hodgkin's disease?. Am. J. Pathol. 1993; 143: 1270
   PubMed Web of Science ®Google Scholar
• Kadin M.E., Muramoto L., Said J. Expression of T-cell antigens on Reed-Sternberg cells in a subset of patients with nodular sclerosing and mixed cellularity Hodgkin's disease. Am. J. Pathol. 1988; 130: 345
   PubMed Web of Science ®Google Scholar
• Casey T.T., Olson S.J., Cousar J.B., Collins R.D. Immunophenotypes of Reed-Stemberg cells: a study of 19 cases of Hodgkin's disease in plastic-embedded sections. Blood 1989; 74: 2624
   PubMed Web of Science ®Google Scholar
• Dallenbach F.E., Stein H. Expression of T-cell receptor beta chain in Reed-Stemberg cells. Lancet 1989; ii: 828
   Google Scholar
• Zukerberg L.R., Collins A.B., Ferry J.A., Harris N.L. Coexpression of CD15 and CD20 by Reed-Stemberg cells in Hodgkin's disease. Am. J. Pathol. 1991; 139: 475
   PubMed Web of Science ®Google Scholar
• Poppema S., Elema J.D., Halie M.R. The significance of intracytoplasmic proteins in Reed-Stemberg cells. Cancer 1978; 42: 1793
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Chilosi M., Caligaris-Cappio F., Fiore-Donati L., Perona G., Janossy G. Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's disease. Br. J. Cancer 1984; 50: 415
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D.Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Stemberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848
   PubMed Web of Science ®Google Scholar
• Poppema S., Bhan A.K., Reinherz E.L., Posner M.R., Schlossman S.F. In situ characterization of cellular constituents in lymph nodes and spleens involved by Hodgkin's disease. Blood 1982; 59: 226
   PubMed Web of Science ®Google Scholar
• Hsu S., Jaffe E. Leu-Ml and peanut agglutinin stain the neoplastic cells of Hodgkin's disease. Am. J. Clin. Pathol. 1984; 82: 29
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Hsu P.L. Lymphocyte functional antigens stabilize agglutination between Reed-Stemberg cells and T cells, but are not responsible for homotypic binding of Hodgkin's Reed-Stemberg cells. Am. J. Pathol. 1990; 137: 5663
   Google Scholar
• Chadburn A., Inghirami G., Knowles D.M. The kinetics and temporal expression of T-cell activation-associated antigens CD15 (LeuM11), CD30 (Ki-1), EMA, and CD11c (LeuM5) by benign activated T cells. Hematol. Pathol. 1992; 66: 193
   Google Scholar
• Durkop H., Latza U., Hummel M., Eitelbach F., Seed B., Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 1992; 68: 421
   PubMed Web of Science ®Google Scholar
• Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., Sutherland G.R., Brannan C.I., Copeland N.G., Jenkins N.A., Grabstein K.H., Gliniak B., McAlister I.B., Fanslow W., Alderson M., Falk B., Gimpel S., Din W.S., Gillis S., Goodwin R.G., Armitage R.J. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993; 73: 1349
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Waldron Hsu P.L., Hough A.J. Cytokines in malignant lymphomas: review and prospective evaluation. Hum. Pathol 1993; 24: 1040
   PubMed Web of Science ®Google Scholar
• O'Grady J.T., Stewart S., Lowrey J., Howie S.E.M., Krajeski A.S. CD40 expression in Hodgkin's disease. Am. J. Pathol. 1994; 144: 21
   PubMed Web of Science ®Google Scholar
• Timens W., Visser L., Poppema S. Nodular lymphocyte predominance type of Hodgkin's disease is a germinal center lymphoma. Lab. Invest. 1986; 54: 457
   PubMed Web of Science ®Google Scholar
• Pinkus G.S., Said J.W. Hodgkin's disease, lymphocyte predominance type, nodular - further evidence for a B cell derivation. L&H variants of Reed-Stemberg cells express L26, a pan B cell marker. Am. J. Pathol. 1988; 133: 211
   PubMed Web of Science ®Google Scholar
• Hell K., Pringle J.H., Hansmann M.L., Lorenzen J., Colloby P., Lauder I., Fischer R. Demonstration of light chain mRNA in Hodgkin's disease. J. Pathol. 1993; 171: 137
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Semenzato G., Chilosi M., Morittu L., Ambrosetti A., Warner N., Bofill M., Janossy G. Distribution and heterogeneity of cells detected by HNK-1 monoclonal antibody in blood and tissues in normal, reactive and neoplastic conditions. Clin. Exp. Immunol. 1984; 57: 195
   PubMed Web of Science ®Google Scholar
• Chilosi M., Doglioni C., Pelosio P., Mombello A., Lestani M., Ennas M.G., Pizzolo G., Scarpa A., Menestrina F. CD4+/CD57+ T-cells of follicular germinal centers react with an antibody recognizing the calcium-binding protein parvalbumin. J. Immunol. Res. 1991; 3: 169
   Google Scholar
• Hsu S.M., Zhao X. Expression of interleukin-1 in Reed-Sternberg cells and neoplastic cells from true histiocytic malignancies. Am. J. Pathol 1986; 125: 221
   PubMed Web of Science ®Google Scholar
• Naumovski L., Utz P.J., Bergstorm S.K., Morgan R., Molina A., Toole I.J., Glader B.E., McFall P., Weiss L.M., Warnke R., Smith S.D. SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood 1989; 74: 2733
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Krupen K., Lachman L.B. Heterogeneity of interleukin-1 production in cultured Reed-Stemberg cell lines HDLM-1, HDLM-1d, and KM-H2. Am. J. Pathol. 1989; 135: 33
   PubMed Web of Science ®Google Scholar
• Kretschmer C., Jones D.B., Morrison K., Schluter C., Feist W., Ulmer A.J., Arnoldi J., Matthes J., Diamantstein T., Flad H.D., Gerdes J. Tumor necrosis factor alpha and lympho-toxin production in Hodgkin's disease. Am J. Pathol. 1990; 137: 341
   PubMed Web of Science ®Google Scholar
• Smoszuk M., Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75: 13
   PubMed Web of Science ®Google Scholar
• Ruco L.P., Pomponi D., Pigott R., Stoppacciaro A., Monardo F., Uccini S., Boraschi D., Tagliabue A., Santoni A., Dejana E., Mantovani A., Baroni C.D. Cytokine production (IL-1 alpha, IL-1 beta and TNF alpha) and endothelial cell activation (ELAM-1 and HLA-DR) in reactive lymphadenitis, Hodgkin' s disease, and in non-Hodgkin's lymphomas: an immunocytochemical study. Am. J. Pathol. 1990; 137: 1163
   PubMed Web of Science ®Google Scholar
• Merz H., Fliedner A., Orscheschek K., Binder T.H., Sebald W., Muller-Hermelink H.K., Feller A.C. Cytokine expression in T-cell lymphomas and Hodgkin's disease. Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am. J. Pathol. 1991; 139: 1173
   PubMed Web of Science ®Google Scholar
• Merz H., Orscheschek K., Renauld J.C., Fliedner A., Herin M., Noel H., Kadin M., Mueller-Hermelink H.K., Van Snick J., Feller A.C. Interleukin-9 expression in human malignant lymphomas: unique association with Hodgkin's disease and large anaplastic lymphoma. Blood 1991; 78: 1311
   PubMed Web of Science ®Google Scholar
• Jucker M., Abts H., Li W., Schindler R., Merz H., Gunther A., von Kalle C., Schaadt M., Diamantstein T., Feller A., Krueger C G.R. F., Diehl V., Blankenstein T., Tesch H. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. Blood 1991; 77: 2413
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Xie S.S., Hsu P.L., Waldron J.A. Interleukin-6, but not interleukin-4, is expressed by Reed-Sternberg cells in Hodgkin's disease with or without histologic features of Castleman's disease. Am. J. Pathol. 1992; 141: 129
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Bostick-Bruton F., Sauder D.N., Scala G., Diehl V. Neoplastic cells obtained from Hodgkin's disease are potent stimulators of human primary mixed lymphocyte cultures. J. Immunol. 1983; 130: 2666
   PubMed Web of Science ®Google Scholar
• Fisher R.I., Cossman J., Diehl V., Volkman D.J. Antigen presentation by Hodgkin's disease cells. J Immunol. 1985; 135: 3568
   PubMed Web of Science ®Google Scholar
• Delabie J., Ceuppens J.L., Vandenberghe P., de Boer M., Coorevits L., De Wolf-Peeters C. The B7/BB1 antigen is expressed by Reed-Stemberg cells of Hodgkin's disease-derived cell lines. Blood 1993; 82: 2845
   PubMed Web of Science ®Google Scholar
• Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Derynck R., Spom M.B., Fauci A.S. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med 1986; 163: 1037
   PubMed Web of Science ®Google Scholar
• Rook A.H., Kehrl J.H., Wakefield L.M., Roberts A.B., Spom M.B., Burlington D.B., Lane H.C., Fauci A.S. Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol. 1986; 136: 3916
   PubMed Web of Science ®Google Scholar
• Wahl S.M., Hunt D.A., Wakefield L.M., McCartney-Francis N., Wahl L.M., Roberts A.B., Spom M.B. Transforming growth factor-beta induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA 1987; 84: 5788
   PubMed Web of Science ®Google Scholar
• Wahl S.M., McCartney-Francis N., Mergenhagen S.E. Inflammatory and immunomodulatory roles of TGFp. Immunol. Today 1989; 10: 258
   PubMedGoogle Scholar
• Roberts A.B., Spom M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., Heine U.I., Liotta L.A., Falanga V., Kehrl J.H., Fauci A.S. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA 1986; 83: 4167
   PubMed Web of Science ®Google Scholar
• Kadin M.E., Agnarsson B.A., Ellingsworth L.R., Newcom S.R. Immunohistochemical evidence of a role for transforming growth factor beta in the pathogenesis of nodular sclerosing Hodgkin's disease. Am. J. Pathol. 1990; 136: 1209
   PubMed Web of Science ®Google Scholar
• Kadin M., Butmarc J., Elovic A., Wong D. Eosinophils are the major source of transforming growth factor-beta in nodular sclerosing Hodgkin's disease. Am. J. Pathol. 1993; 142: 11
   PubMed Web of Science ®Google Scholar
• Wang J.M., Rambaldi A., Biondi A., Chen Z.G., Sanderson C.J., Mantovani A. Recombinant human interleukin-5 is a selective eosinophil chemoattractant. Eur. J. Immunol. 1989; 19: 701
   PubMed Web of Science ®Google Scholar
• Sanderson C.J., Campbell H.D., Young J.G. Molecular and cellular biology of eosinophil differentiation factor (interleukin 5) and its effects on human and mouse B-cells. Immunol. Rev. 1988; 102: 29
   PubMed Web of Science ®Google Scholar
• Romagnani S., Rossi Ferrini P.L., Ricci M. The immune derangement in Hodgkin's disease. Sem. Hematoi 1985; 22: 41
   PubMed Web of Science ®Google Scholar
• Slivnick D.J., Ellis T.M., Nawrocki J.F., Fisher R.I. The impact of Hodgkin's disease on the immune system. Sem. Oncol. 1990; 17: 673
   PubMed Web of Science ®Google Scholar
• Pearson C.A., Pearson D., Shibahara S., Hofsteenge J., Chiquet-Ehrismann R. Tenascin: cDNA cloning and induction by TGF-β. EMBO J. 1988; 7: 2677
   Google Scholar
• Roberts A.B., McCune B.K., Spom M.B. TGF-B: regulation of extracellular matrix. Kidney Intern. 1992; 41: 557
   PubMed Web of Science ®Google Scholar
• Chiquet-Ehrismann R., Kalla P., Pearson C.A., Beck K., Chiquet M. Tenascin interfers with fibronectin action. Cell 1988; 53: 383
   PubMed Web of Science ®Google Scholar
• Lightner V.A., Erickson H.P. Binding of hexabrachion (tenascin) to the extracellular matrix and substratum and its effect on cell adhesion. J. Cell. Sci. 1990; 95: 263
   PubMed Web of Science ®Google Scholar
• Chilosi M., Lestani M., Benedetti A., Montagna L., Pedron S., Scarpa A., Menestrina F., Hirohashi S., Pizzolo G., Semenzato G. Constitutive expression of tenascin in T-de-pendent zones of human lymphoid tissues. Am. J. Pathol 1993; 143: 1348
   PubMed Web of Science ®Google Scholar
• Ruegg C.R., Chiquet-Ehrismann R., Alkan S.S. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc. Natl. Acad. Sci. USA 1989; 866: 7437
   Web of Science ®Google Scholar
• Chilosi M., Mombello A., Montagna L., Benedetti A., Lestani M., Semenzato G., Menestrina F. Multimarker immunohistochemical staining of calgranulins, chloroacetate esterase, and S100 for simultaneous demonstration of inflammatory cells on paraffin sections. J. Histochem. Cytochem. 1990; 38: 1669
   PubMed Web of Science ®Google Scholar
• Ree H.J. Stromal macrophage-histiocytes in Hodgkin's disease. Their relation to fever. Cancer 1987; 60: 1479
   PubMed Web of Science ®Google Scholar
• Butterfield J.H., Leiferman K.M., Abrams J., Silver J.E., Bower J., Gonchoroff N., Gleich G.J. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood 1992; 79: 688
   PubMed Web of Science ®Google Scholar
• Dinarello C.A., Wolff S.M. The role of interleukin-1 in disease. N. Engl. J. Med. 1993; 328: 106
   PubMed Web of Science ®Google Scholar
• Hsu S.M., Zhao X. Expression of interleukin-1 in Reed-Stemberg cells and neoplastic cells from true histiocytic malignancies. Am. J. Pathol. 1986; 125: 221
   PubMed Web of Science ®Google Scholar
• Ruco L.P., Pomponi D., Pigott R., Gearing A.J.H., Baiocchini A., Baroni C.D. Expression and cell distribution of the intercellular adhesion molecule, vascular cell adhesion molecule, and endothelial cell adhesion molecule (CD31) in reactive human lymph nodes and in Hodgkin's disease. Am. J. Pathol. 1992; 140: 1337
   Web of Science ®Google Scholar
• Pizzolo G., Vinante R., Nadali G., Ricetti M.M., Morosato L., Marrocchella R., Vincenzi C., Semenzato G., Chilosi M. ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. Br. J. Haematol. 1993; 84: 161
   PubMed Web of Science ®Google Scholar
• Fujimoto J., Levy S., Levy R. Spontaneous release of the Leu-2 (T8) molecule from human T cells. J. Exp. Med. 1983; 159: 752
   Web of Science ®Google Scholar
• Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson D.L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol. 1985; 135: 3172
   PubMed Web of Science ®Google Scholar
• Nelson D.L., Rubin L.A., Kurman C.C., Fritz M.E., Boutin B. An analysis of the cellular requirements for the production of soluble interleukin 2 receptors in vitro. J. Clin. Immunol. 1986; 6: 114
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Chilosi M., Semenzato G. The soluble in-terleukin-2 receptor in haematological disorders. Annotation. Br. J. Haematol. 1987; 67: 377
   PubMed Web of Science ®Google Scholar
• Josimovic-Alasevic Q., Durkop H., Schwarting R., Backe E., Stein H., Diamantstein T. Ki1 (CD30) antigen is released by Ki1 positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. Eur. J. Immunol. 1989; 19: 157
   PubMed Web of Science ®Google Scholar
• Lantz M., Gullberg U., Nilsson E., Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein. A soluble form of a tumor necrosis factor receptor. J. Clin. Invest 1990; 86: 1396
   PubMed Web of Science ®Google Scholar
• Kohno T., Brewer M.T., Baker S.L., Schwartz P.E., King M.W., Hale K.K., Squires C.H., Thompson R.C., Vannice J.L. A second tumor necrosis factor receptor gene product can shed a naturally occurring tumor necrosis factor inhibitor. Proc. Natl. Acad. Sci. USA 1990; 87: 8331
   PubMed Web of Science ®Google Scholar
• Tomkinson B.E., Wagner D.K., Nelson D.L., Sullivan J.L. Activated lymphocytes during acute Epstein-Barr virus infection. J. Immunol. 1987; 139: 3802
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore-Donati L., Perona G., Berton G., Lestani M., Scarpa A., Agostini C., Trentin L., Zambello R., Masciarelli M., Dazzi F., Vinante F., Caligaris-Cappio F., Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-inter-feron therapy on clinical parameters and natural killer in vitro activity. Blond 1987; 70: 1530
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Chilosi M., Vinante F., Dazzi F., Lestani M., Perona G., Benedetti F., Todeschini G., Vincenzi C., Trentin L., Semenzato G. Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. Br. J. Cancer 1987; 55: 427
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levelsof solubleinterleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features. Am. J. Clin. Pathol. 1989; 92: 186
   PubMed Web of Science ®Google Scholar
• Pui C.H., Ip S.H., Thompson E., Wilimas J., Brown M., Dodge R.K., de Hoyos R.A., Berard C.W., Crist W.M. High serum interleukin-2 receptor levels correlate with a poor prognosis in children with Hodgkin's disease. Leukemia 1989; 3: 481
   PubMed Web of Science ®Google Scholar
• Pui C.H., Ip S.H., Thompson E., Dodge A.K., Brown M., Wilimas J., Carrabis S., Kung P., Berard C.W., Crist W.M. Increased serum CD8 antigen level in childhood Hodgkin' s disease relates to advanced stage and poor treatment outcome. Blood 1989; 73: 209
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Vinante F., Chilosi M., Dallenbach F., Josimovic-Alasevic O., Diamantstein T., Stein H. Serum levels of soluble CD30 molecule (Kl-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. Br. J. Haematol. 1990; 75: 282
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Vinante F., Ambrosetti A., Chilosi M., Romagnani S., Diamantstein T., Stein H. Soluble molecules in lymphoproliferative diseases. Immunological aspects of malignant lymphomas and cryoglobulinemia. Ermes Milano 1990; 91
   Google Scholar
• Gause A., Pohl C., Tschiersch A., Da Costa L., Jung W., Diehl V., Hasenclever D., Pfreundschuh M. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease. Blood 1991; 77: 1983
   PubMed Web of Science ®Google Scholar
• Rothlein R., Mainolfi E.A., Czajkowski M., Marlin S.D. A form of circulating ICAM-1 in human serum. J. Immunol. 1991; 147: 3788
   PubMed Web of Science ®Google Scholar
• Gause A., Jung W., Shmits R., Tschiersch A., Scholz R., Pohl C., Hasenclever D., Diehl V., Pfreundschuh M. Soluble CD8, CD25, and CD30 antigens as prognostic markers in patients with untreated Hodgkin's lymphoma. Ann. Oncol. 1992; 3(Suppl.)S49
   PubMedGoogle Scholar
• Ambrosetti A., Nadali G., Vinante F., Carlini S., Veneri D., Todeschini G., Morosato L., de Sabata D., Chilosi M., Maggi E., Parronchi P., Romagnani S., Semenzato G., Perona G., Pizzolo G. Serum levels of soluble interleukin-2 receptor in Hodgkin's disease: relationship with clinical stage, tumor burden and treatment outcome. Cancer 1993; 72: 201
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Dolken G., Brach M.A., Mertelsmann R., Herrmann F. Serum levels of circulating ICAM-1 are increased in Hodgkin's disease. Leukemia 1993; 7: 1245
   PubMed Web of Science ®Google Scholar
• Gruss H.J., Dolken G., Brach M.A., Mertelsmann R., Herrmann F. The significance of serum levels of soluble 60 kDa receptors for tumor necrosis factor in patients with Hodgkin's disease. Leukemia 1993; 7: 1339
   PubMed Web of Science ®Google Scholar
• Pui C.H., Luo X., Evans W., Martin S., Rugg A., Wilimas J., Crist W.M., Hudson M. Serum intercellular adhesion molecule-1 in childhood. Malignancy 1993; 82: 895
   Google Scholar
• Pizzolo G., Vinante F., Nadali G., Chilosi M., Semenzato G. Circulating soluble ICAM-1 in patients with Hodgkin's disease. Immunol. Today 1994; 15: 140
   PubMedGoogle Scholar
• Nadali G., Vinante F., Ambrosetti A., Todeschini G., Veneri D., Zanotti R., Meneghini V., Ricetti M.M., Benedetti F., Vassanelli A., Perona G., Chilosi M., Menestrina F., Fiacchini M., Stein H., Pizzolo G. Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J. Clin. Oncol. 1994; 12: 793
   PubMed Web of Science ®Google Scholar
• Tomkinson B.E., Brown M.C., Ip S.H., Carrabis S., Sullivan J.L. Soluble CD8 during T cell activation. J. Immunol. 1989; 142: 2230
   PubMed Web of Science ®Google Scholar
• Akbar A.N., Borthwick N., Salmon M., Gombert W., Bofill M., Shamsadeen N., Pilling D., Pett S., Grandy S.E., Janossy G. The significance of low bcl-2 expression by CD45RO T cells in normal individuals and patients with acute viral infections. The role of apoptosis in T cell memory. J. Exp. Med. 1993; 178: 427
   PubMed Web of Science ®Google Scholar
• Becker J.C., Dummer R., Hartmann A.A., Burg G., Schmidt E. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-y and tumor necrosis factor-a: functional consequences on cell-mediated cytotoxicity. J. Immunol. 1991; 147: 4398
   PubMed Web of Science ®Google Scholar
• Welder C.A., Lee D.H.S., Takei F. Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. J. Immunol. 1993; 150: 2203
   PubMed Web of Science ®Google Scholar
• Rubin L.A., Jay G., Nelson D.L. The released inter-leukin 2 receptor binds interleukin 2 efficiently. J. Immunol. 1986; 137: 3841
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Vincenzi C., Vinante F., Rigo A., Veneri D., Chilosi M., Dusi S., Poli G., Zambello R., Semenzato G., Berton G. Highly concentrated urine-purified Tac peptide fails to inhibit IL-2 dependent cell proliferation in vitro. Cell. Immunol. 1992; 141: 253
   PubMed Web of Science ®Google Scholar
• Jacques Y., LeMauff B., Boeffard F., Godard A., Soulillou J.P. A soluble interleukin 2 receptor produced by a normal alloreactive human T cell clone binds interleukin 2 with low affinity. J. Immunol. 1987; 139: 2308
   PubMed Web of Science ®Google Scholar
• Waage A., Liabakk N., Lien E., Lamvik J., Espevik T. p55 and p75 tumor necrosis factor receptors in patients with chronic lymphocytic leukemia. Blood 1992; 80: 2577
   PubMed Web of Science ®Google Scholar
• Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 1989; 264: 1966
   Google Scholar
• Gruss H.J., Dolken G., Brach M.A., Mertelsmann R., Herrmann F. High concentrations of the interleukin-1 receptor antagonist in serum of patients with Hodgkin's disease. Lancet 1992; 340: 968
   PubMed Web of Science ®Google Scholar